Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,368 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $24.72, for a total transaction of $58,536.96. Following the sale, the insider now owns 62,629 shares of the company's stock, valued at $1,548,188.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Castle Biosciences Stock Down 1.1 %
Shares of CSTL stock traded down $0.26 during trading hours on Wednesday, hitting $23.54. 267,431 shares of the company's stock traded hands, compared to its average volume of 241,626. The stock's fifty day simple moving average is $20.83 and its two-hundred day simple moving average is $20.59. Castle Biosciences, Inc. has a 12-month low of $9.26 and a 12-month high of $26.70. The stock has a market cap of $649.94 million, a price-to-earnings ratio of -20.47 and a beta of 0.93. The company has a quick ratio of 9.02, a current ratio of 9.25 and a debt-to-equity ratio of 0.02.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 12.28% and a negative return on equity of 7.91%. The firm had revenue of $66.12 million during the quarter, compared to analyst estimates of $51.32 million. On average, analysts expect that Castle Biosciences, Inc. will post -2.41 EPS for the current year.
Analysts Set New Price Targets
Several brokerages have commented on CSTL. Scotiabank raised their price objective on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Friday, March 1st. KeyCorp raised their price objective on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, March 1st. Finally, Robert W. Baird raised their price objective on shares of Castle Biosciences from $33.00 to $34.00 and gave the stock an "outperform" rating in a report on Friday, May 3rd.
Check Out Our Latest Analysis on CSTL
Hedge Funds Weigh In On Castle Biosciences
Several large investors have recently made changes to their positions in CSTL. Deerfield Management Company L.P. Series C purchased a new position in shares of Castle Biosciences during the third quarter valued at approximately $15,988,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Castle Biosciences by 112.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 547,403 shares of the company's stock valued at $9,246,000 after purchasing an additional 289,252 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Castle Biosciences during the third quarter valued at approximately $2,885,000. Intrinsic Edge Capital Management LLC increased its position in shares of Castle Biosciences by 108.8% during the fourth quarter. Intrinsic Edge Capital Management LLC now owns 326,270 shares of the company's stock valued at $7,041,000 after acquiring an additional 170,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its position in shares of Castle Biosciences by 59.0% during the fourth quarter. Parkman Healthcare Partners LLC now owns 357,156 shares of the company's stock valued at $7,707,000 after acquiring an additional 132,564 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
